GRCENasdaqPharmaceutical PreparationsFiscal year ends March 31
Grace Therapeutics, Inc.
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$1.88−0.01 (-0.53%)
Close on Oct 19, 2026
- Market cap
- $32.47M
- P/E (TTM)
- –
- Dividend yield
- –
Grace Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Grace Therapeutics | Industry median |
|---|---|---|
| Market Cap | $39.55M | $166.30M |
| Enterprise Value | $25.79M | $88.19M |
| PB Ratio | 0.82 | 2.03 |
| P/TBV Ratio | 3.17 | 2.29 |
Income (trailing twelve months)
| Measure | Grace Therapeutics | Industry median |
|---|---|---|
| Operating Income | -$23.91M | -$21.40M |
| Pretax Income | -$21.92M | -$14.34M |
| Net Income | -$20.22M | -$22.46M |
| EBITDA | -$23.91M | -$16.91M |
| EPS (Diluted) | -$1.18 | -$0.83 |
Returns
| Measure | Grace Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -36.2% | -53.2% |
| Return on Assets (ROA) | -33.7% | -40.9% |
| Return on Invested Capital (ROIC) | -39.3% | -32.4% |
| Return on Capital Employed (ROCE) | -49.0% | -38.1% |
Balance sheet
| Measure | Grace Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $13.76M | $61.43M |
| Net Cash (Debt) | $13.76M | $15.35M |
| Net Cash Per Share | $0.65 | $0.66 |
| Equity (Book Value) | $48.21M | $49.09M |
| Book Value Per Share | $2.29 | $1.37 |
| Tangible Book Value | $12.48M | $23.52M |
| Working Capital | $13.08M | $76.81M |
Financial position
| Measure | Grace Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 11.47 | 3.34 |
| Quick Ratio | 11.00 | 2.44 |
Cash flow (trailing twelve months)
| Measure | Grace Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$10.29M | -$12.35M |
Efficiency
| Measure | Grace Therapeutics | Industry median |
|---|---|---|
| Profits Per Employee | -$4.04M | -$703.34K |
| Employee Count | 5 | 74 |
Dividends and yields
| Measure | Grace Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -51.1% | -23.3% |
Shares
| Measure | Grace Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 21,035,900 | 58,127,000 |
| Shares Change (YoY) | 27.7% | 10.9% |
| Shares Change (QoQ) | 1.56% | 0.54% |
| Float | 13,088,800 | 49,136,700 |
| Shares Held by Insiders | 37.8% | 11.6% |
| Shares Held by Institutions | 18.8% | 59.4% |
Taxes
| Measure | Grace Therapeutics | Industry median |
|---|---|---|
| Income Tax | -$1.70M | $79.87K |
Scores
| Measure | Grace Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | 4.65 | -0.22 |
| Piotroski F-Score | 2 | 4 |
Calculated by StockData from Grace Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.